4 active not recruiting, 3 not yet recruiting, 3 recruiting. 10 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Active not recruiting 4, Not yet recruiting 3, Recruiting 3 |
Follow SHR-A1811: new trials by email Literature Review of SHR-A1811 trials Research Report on SHR-A1811
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of HER2-Targeted Antibody-Drug Conjugates Compared With Hormone-Based Therapy for Hormone Receptor-Positive, HER2-Low Metastatic Breast Cancer Trastuzumab Deruxtecan, SHR-A1811, Hormone Receptor-Directed Therapy - Metastatic Breast Cancer, Hormone Receptor-Positive Breast Cancer | Phase 3 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 288 | 2026-11-01 | 2026-11-20 |
| Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype SHR-A1811, Famitinib+SHR-A1811 - Breast Cancer | Phase 3 | Not yet recruiting | Fudan University | 248 | 2026-02-26 | 2026-02-03 |
| SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer SHR-A1811, Chemotherapy - Ovarian Cancer | Phase 3 | Not yet recruiting | Tongji Hospital | 300 | 2025-06-01 | 2025-05-25 |
| A Study of SHR-A1811 in Subjects With Ovarian Cancer SHR-A1811, Paclitaxel Injection, Doxorubicin Hydrochloride Liposome Injection - Ovarian Cancer | Phase 3 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 300 | 2025-03-13 | 2026-04-20 |
| A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations SHR-A1811, PD-1/PD-L1 inhibitorsăPemetrexed/ PaclitaxelăCarboplatin/ Cisplatin - Non-Small Cell Lung Cancer With HER2- Mutations | Phase 3 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 300 | 2024-07-29 | 2026-01-21 |
| Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan SHR-A1811, TAS-102, Regorafenib , Fruquintinib - Advanced Colorectal Cancer | Phase 3 | Active not recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 130 | 2024-03-01 | 2025-07-17 |
| SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen SHR-A1811, Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan - HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 360 | 2024-01-09 | 2024-01-16 |
| A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy SHR-A1811, Trastuzumab Emtansine - HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy | Phase 3 | Active not recruiting | Jiangsu HengRui Medicine Co., Ltd. | 1615 | 2023-11-20 | 2026-06-30 |
| SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial SHR-A1811, Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel - Breast Cancer | Phase 3 | Active not recruiting | Jiangsu HengRui Medicine Co., Ltd. | 551 | 2023-06-30 | 2026-08-06 |
| A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane SHR-A1811, Pyrotinib in combination with Capecitabine. - HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane | Phase 3 | Active not recruiting | Jiangsu HengRui Medicine Co., Ltd. | 381 | 2022-08-04 | 2025-08-22 |
Breast Neoplasms (3) · Ovarian Neoplasms (2)
Jiangsu HengRui Medicine Co., Ltd. (6) · Fudan University (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (1) · Tongji Hospital (1)
China (10)
Qinglei Gao (1)